Liraglutide's Blood Pressure Lowering Time Course and Mechanism in Type 2 Diabetes Patients Under Investigation

Type 2 diabetes is a global health challenge, often accompanied by hypertension, a major modifiable risk factor for adverse cardiovascular outcomes. While blood pressure reduction is strongly linked to improved cardiovascular health, the specific antihypertensive potential of liraglutide has been observed in preclinical studies. However, the precise time course and underlying mechanisms of this effect in human patients remain largely unknown, representing a critical gap in understanding its full therapeutic benefits beyond glycemic control. This study aims to bridge that knowledge gap.